Novartis sheds light on liquid biopsies with SOLAR-1 analysis

A new analysis of the SOLAR-1 study of Novartis' alpelisib showed the drug, when paired with hormone therapy, improved median progression free survival (PFS) by 11 months for PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer patients, compared to 6.8 months for patients only receiving the hormone therapy.